@article{APS11119,
author = {Jing-fen Su and Yue Xiao and Lin-yu Wei and Hui-yang Lei and Fei Sun and Wei-xia Wang and Shi-hong Li and Xiao-chuan Wang and Jie Zheng and Jian-zhi Wang},
title = {A new tau dephosphorylation-targeting chimera for the treatment of tauopathies},
journal = {Acta Pharmacologica Sinica},
volume = {45},
number = {11},
year = {2024},
keywords = {},
abstract = {Abnormal accumulation of hyperphosphorylated tau protein plays a pivotal role in a collection of neurodegenerative diseases named tauopathies, including Alzheimer’s disease (AD). We have recently conceptualized the design of hetero-bifunctional chimeras for selectively promoting the proximity between tau and phosphatase, thus specifically facilitating tau dephosphorylation and removal. Here, we sought to optimize the construction of tau dephosphorylating-targeting chimera (DEPTAC) and obtained a new chimera D14, which had high efficiency in reducing tau phosphorylation both in cell and tauopathy mouse models, while showing limited cytotoxicity. Moreover, D14 ameliorated neurodegeneration in primary cultured hippocampal neurons treated with toxic tau-K18 fragments, and improved cognitive functions of tauopathy mice. These results suggested D14 as a cost-effective drug candidate for the treatment of tauopathies.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/11119}
}